Is AEG a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Aegon Ltd. (AEG) rests on Becoming an American company on paper, not just in practice: Aegon has picked Delaware for its legal seat, New York City for a headquarters opening around mid-2027, and January 1, 2028 as the date the holding company becomes Transamerica Inc. The bear case rests on the legacy American book is the reason the multiple is low: Transamerica carries long-term care and older universal life liabilities whose reserve adequacy depends on morbidity, mortality, lapse and claim-cost assumptions that get revisited annually, and an adverse review can wipe out a year of earnings growth in one press release. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Aegon Ltd is a life insurance and retirement group whose center of gravity has shifted almost entirely to the United States. The dominant business is Transamerica, which sells individual life insurance, annuities, workplace retirement plans and mutual funds, and distributes much of that through World Financial Group, an agent network that passed 95,000 licensed agents during 2025. Outside the US, the group runs a UK workplace pensions and adviser platform, a joint venture with Santander across Spain and Portugal, an interest in Mongeral Aegon in Brazil, and an asset management arm. The company sold its Dutch insurance operations to a.s.r. in 2023 and has been steadily simplifying what remains. Roughly 15,300 people work there, and the reporting currency is still the euro even though the earnings are overwhelmingly dollar-denominated. The investment picture is a capital-return case wrapped around a corporate reorganization. Full-year 2025 brought an operating result of about EUR 1.7 billion (up 15 percent), operating capital generation of about EUR 1.3 billion against a EUR 1.2 billion target, and a net result of roughly EUR 980 million. Management returned about EUR 1.1 billion through dividends and buybacks and guided the 2025 to 2027 transition period toward roughly 5 percent annual growth in the operating result and free cash flow, with dividend growth above 5 percent a year from a base of about EUR 0.40 per share. In May 2026 Aegon reached an agreement with Vereniging Aegon, its long-standing anchor shareholder, and published a US-aligned governance proposal; shareholders are expected to vote on redomiciliation at an extraordinary meeting in the fourth quarter of 2026, with the holding company scheduled to be renamed Transamerica Inc. by January 1, 2028. The shares have roughly doubled off their 52-week low and still change hands near 9 to 10 times forward earnings, which tells you the market is pricing the legacy American life liabilities, not the growth.
The bull case for AEG
1. Becoming an American company on paper, not just in practice
Aegon has picked Delaware for its legal seat, New York City for a headquarters opening around mid-2027, and January 1, 2028 as the date the holding company becomes Transamerica Inc. The May 2026 agreement with Vereniging Aegon and the accompanying governance proposal removed a structural overhang that had made the shares awkward for US institutional buyers. If the fourth-quarter 2026 shareholder vote passes and index treatment follows, the pool of natural owners widens considerably.
2. Capital generation drives a mechanical return of cash
Operating capital generation of about EUR 1.3 billion in 2025 and free cash flow of about EUR 829 million fund a payout policy that has been unusually explicit for the sector. The 2025 dividend of EUR 0.40 per share came alongside a fresh EUR 400 million buyback for 2026, split evenly across the two halves. With a shrinking share count and stated dividend growth above 5 percent annually, the per-share arithmetic improves even in a flat operating year.
3. Transamerica's distribution engine
World Financial Group crossed 95,000 licensed agents and helped deliver a record 30 percent increase in individual new life sales in 2025 over 2024. Owning proprietary distribution matters in US life, where most competitors rent shelf space from independent marketing organizations and pay for the privilege. Whether the agent count converts into persistent, profitable premium rather than churn is the number worth watching each half.
4. Simplifying everything outside the United States
The Dutch business went to a.s.r. in 2023, and management has kept trimming stakes and non-core lines since. What is left internationally is a UK platform, a Santander partnership in Iberia, a Brazilian joint venture and asset management, each of which is a candidate for sale, partnership or continued cash extraction. Every disposal shortens the story to one sentence about American life and retirement, which is what the redomiciliation is meant to deliver.
The bear case for AEG
The legacy American book is the reason the multiple is low: Transamerica carries long-term care and older universal life liabilities whose reserve adequacy depends on morbidity, mortality, lapse and claim-cost assumptions that get revisited annually, and an adverse review can wipe out a year of earnings growth in one press release. Earnings and capital are sensitive to interest rates, credit spreads and equity markets at the same time, so a credit cycle that hits the fixed income portfolio while equity-linked fee income falls would pressure both sides. The redomiciliation is not finished: it needs a shareholder vote expected in the fourth quarter of 2026, regulatory clearance, and a transition of the group's capital framework from Bermuda and Solvency II toward US-style supervision, and any of those can slip. Reporting stays in euros while cash flows are mostly dollars, so translation adds noise that has nothing to do with underlying performance. Rate competition in annuities from well-capitalized private-credit-backed rivals can also compress spreads faster than the company's own repricing cycle.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding AEG already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on AEG
Too few analysts publish on AEG for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The AEG forecast page covers what coverage does exist.
How is AEG valued? (as of August 2026)
Snapshot for AEG as of August 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Share price / market cap: ~$9.45, ~$14.2 billion on ~1.51 billion shares
- Revenue (TTM): ~$14.3 billion
- Net income (TTM): ~$1.08 billion, EPS ~$0.69
- P/E: ~13x trailing, ~9.5x forward
- Operating capital generation (FY2025): ~EUR 1.3 billion, above the ~EUR 1.2 billion target
- Dividend: ~EUR 0.40 per share for 2025 (~$0.47), roughly a ~4.7% trailing yield
Aegon reports in euros on a half-yearly calendar, so the trailing US-dollar figures above are converted and will not line up exactly with the company's own releases. The most recent full set is the second-half and full-year 2025 report published February 19, 2026, which showed an operating result of about EUR 1.7 billion (up 15 percent) and a net result of about EUR 980 million (up 45 percent). First-half 2026 results are scheduled for August 20, 2026, and the numbers above sit ahead of that print.
How do you decide if AEG is a buy?
Rather than asking whether AEG is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold AEG indirectly through an index or sector ETF before adding more.
What would change your mind on AEG
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Becoming an American company on paper, not just in practice stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: the legacy American book is the reason the multiple is low: Transamerica carries long-term care and older universal life liabilities whose reserve adequacy depends on morbidity, mortality, lapse and claim-cost assumptions that get revisited annually, and an adverse review can wipe out a year of earnings growth in one press release fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the AEG stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about AEG against your real portfolio and see your actual exposure before deciding.
Investing in Aegon Ltd. with AI
Connect the broker you already use and ask Walnut's AI how AEG fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is AEG a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Becoming an American company on paper, not just in practice, with revenue (ttm) at ~$14.3 billion. The bear case rests on the legacy American book is the reason the multiple is low: Transamerica carries long-term care and older universal life liabilities whose reserve adequacy depends on morbidity, mortality, lapse and claim-cost assumptions that get revisited annually, and an adverse review can wipe out a year of earnings growth in one press release. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell AEG?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The legacy American book is the reason the multiple is low: Transamerica carries long-term care and older universal life liabilities whose reserve adequacy depends on morbidity, mortality, lapse and claim-cost assumptions that get revisited annually, and an adverse review can wipe out a year of earnings growth in one press release. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.
What is the bull case for AEG?
+
Becoming an American company on paper, not just in practice. Aegon has picked Delaware for its legal seat, New York City for a headquarters opening around mid-2027, and January 1, 2028 as the date the holding company becomes Transamerica Inc.
What is the bear case for AEG?
+
The legacy American book is the reason the multiple is low: Transamerica carries long-term care and older universal life liabilities whose reserve adequacy depends on morbidity, mortality, lapse and claim-cost assumptions that get revisited annually, and an adverse review can wipe out a year of earnings growth in one press release. Earnings and capital are sensitive to interest rates, credit spreads and equity markets at the same time, so a credit cycle that hits the fixed income portfolio while equity-linked fee income falls would pressure both sides. The redomiciliation is not finished: it needs a shareholder vote expected in the fourth quarter of 2026, regulatory clearance, and a transition of the group's capital framework from Bermuda and Solvency II toward US-style supervision, and any of those can slip. Reporting stays in euros while cash flows are mostly dollars, so translation adds noise that has nothing to do with underlying performance. Rate competition in annuities from well-capitalized private-credit-backed rivals can also compress spreads faster than the company's own repricing cycle.
What does Aegon Ltd. do?
+
Aegon is a life insurance and retirement group whose earnings now come overwhelmingly from its US Transamerica business.
What would have to change for AEG to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Becoming an American company on paper, not just in practice) stalling in the reported numbers rather than in the narrative, the risk above (the legacy American book is the reason the multiple is low: Transamerica carries long-term care and older universal life liabilities whose reserve adequacy depends on morbidity, mortality, lapse and claim-cost assumptions that get revisited annually, and an adverse review can wipe out a year of earnings growth in one press release) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What company trades under the ticker AEG?
+
AEG is Aegon Ltd, a life insurance and retirement group whose main operating business in the United States is Transamerica. The NYSE line consists of New York Registry Shares that have traded since November 1991 and correspond one for one with the Amsterdam-listed ordinary shares.
Why is Aegon moving to the United States?
+
Most of the group's earnings and capital already come from Transamerica, so management argues the legal home should match the economics. Aegon plans a Delaware legal seat, a New York City headquarters opening around mid-2027, and a rename of the holding company to Transamerica Inc. by January 1, 2028, with a shareholder vote expected in the fourth quarter of 2026.
Walnut is informational, not investment advice, and gives no verdict on AEG. Analyst targets referenced here come from a August 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.